Where Will Pfizer (PFE) Be in 5 Years?
Five years ago, the eyes of the world were on (NYSE: PFE). The big drugmaker was racing to develop a COVID-19 vaccine with its partner, BioNTech (NASDAQ: BNTX). Its stock was poised for a huge gain once that vaccine launched. In general, Pfizer was on the ascent.
It's a different story today. Sales for Pfizer's COVID-19 vaccine have declined significantly. The company has encountered clinical setbacks. Its stock has plunged roughly 60% below its late 2021 peak. Pfizer is no longer on the ascent.
But where will Pfizer be in five years? Here are five answers to that question.
Source Fool.com
Pfizer Inc. Aktie
23,24 €
1,29 %
Leichte Buy-Präferenz bei der Pfizer Inc. Aktie.
Ein positives, wenn auch nicht starkes, Potenzial für Pfizer Inc. mit einem Kursziel von 27 € im Vergleich zu 23.24 €.
